Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of Formula I, or a ~~including~~ pharmaceutically acceptable ~~salts~~ salt thereof



I

wherein R^1 is selected from the group consisting of H, Cl, F, and C_{1-4}alkyl, where C_{1-4}alkyl is optionally substituted with 1-3 halogen atoms independently selected from F and Cl;

R^2 is selected from the group consisting of H, Cl, F, C_{1-4}alkyl, OC_{1-4}alkyl, and $-S(O)_2CH_3$, where C_{1-4}alkyl and OC_{1-4}alkyl are optionally substituted with 1-3 halogen atoms independently selected from F and Cl;

R^3, R^4 and R^5 are independently selected from the group consisting of hydrogen, F, Cl, C_{1-3}alkyl, and $-OC_{1-3}$alkyl, where C_{1-3}alkyl and $-OC_{1-3}$alkyl are optionally substituted with 1-3 halogens independently selected from F and Cl;

X and Y are each independently selected from the group consisting of O, S, SO, and SO_2; and

n represents an integer selected from 1, 2, 3, and 4.

2. (currently amended) ~~A~~ The compound according to Claim 1 wherein R^2 is selected from H, F, $-OC_{1-3}$ alkyl, and $-S(O)_2CH_3$, where $-OC_{1-3}$ alkyl is optionally substituted with 1-3 F atoms.

3. (currently amended) ~~A~~ The compound according to Claim 1, wherein

R^1 is selected from Cl and n-propyl;

R^2 is selected from H and F; and

R^3, R^4 and R^5 are H.

4. (currently amended) ~~A~~ The compound according to Claim 1, wherein R^2 is $-OCH_2CH_3$ or $-OCH_2CF_3$.

5. (currently amended) ~~A~~ The compound according to Claim 1, wherein R^5 is H; and R^3 and R^4 are each independently selected from H, F, CH_3, CF_3, $-OCH_3$, $-OCF_3$, $-OCH_2CH_3$ and $-OCH_2CF_3$. ~~In other preferred groups of compounds, R^3 and R^4 are H, and R5 is selected from the group consisting of H, F, CH_3, CF_3, OCH_3, OCF_3, OCH_2CH_3 and OCH_2CF_3.~~

6. (currently amended) ~~A~~ The compound according to Claim 1, wherein X and Y are each independently selected from O and S.

7. (currently amended) ~~A~~ The compound according to Claim 1, wherein X and Y are each O.

8. (currently amended) ~~A~~ The compound according to Claim 1, wherein the group X is attached to the phenyl of the N-cyclohexylaminocarbonyl benzenesulfonamide moiety at the position that is meta to the sulfonamide group.

9. (currently amended) ~~A~~ The compound according to Claim 1, wherein the group X is attached to the phenyl of the N-cyclohexylaminocarbonyl benzenesulfonamide moiety at the position that is para to the sulfonamide group.

10. (currently amended) ~~A~~ The compound according to Claim 1, wherein n is 1-3.

11. (currently amended) ~~A~~ The compound according to Claim 1, wherein n is 3 or 4.

12. (currently amended) ~~A~~ The compound according to Claim 1, wherein X and Y are O; n is an integer selected from 1-3; R^3, R^4 and R^5 are H; R^1 is selected from n-propyl and Cl; and R^2 is selected from H, F, and $-S(O)_2CH_3$.

13. (currently amended) ~~A~~ The compound according to Claim 1, wherein R^1 is C_{2-3} alkyl, which is optionally substituted with 1-3 F atoms.

14. (currently amended) ~~A~~ The compound according to Claim 1, wherein R^1 is n-propyl.

15. (currently amended) ~~A~~ The compound which is selected from the compounds below, or a ~~in Examples 1-9, and~~ pharmaceutically acceptable ~~salts thereof.~~ salt thereof:















 , and



16. (original) A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

17. (original) A method for treating hyperglycemia in a mammalian or human patient having non-insulin dependent (Type 2) diabetes mellitus which comprises administering to said patient a therapeutically effective amount of a compound of Claim 1.

18. Canceled

19. Canceled

20. Canceled

21. Canceled

22. Canceled

23. Canceled

24. Canceled

25. (original) A method of treating or controlling one or more diseases, disorders, or conditions selected from the group consisting of (1) non-insulin dependent diabetes mellitus (NIDDM), (2) hyperglycemia, (3) low glucose tolerance, (4) insulin resistance, (5) obesity, (6) lipid disorders, (7) dyslipidemia, (8) hyperlipidemia, (9) hypertriglyceridemia, (10) hypercholesterolemia, (11) low HDL levels, (12) high LDL levels, (13) atherosclerosis and its sequelae, (14) vascular restenosis, (15) irritable bowel syndrome, (16) inflammatory bowel disease, including Crohn's disease and ulcerative colitis, (17) other inflammatory conditions, (18) pancreatitis, (19) abdominal obesity, (20) neurodegenerative disease, (21) retinopathy, (22) neoplastic conditions, (23) adipose cell tumors, (24) adipose cell carcinomas, such as liposarcoma, (25) prostate cancer and other cancers, including gastric, breast, bladder and colon cancers, (26) angiogenesis, (27) Alzheimer's disease, (28) psoriasis, (29) high blood pressure, (30) Syndrome X, (31) ovarian hyperandrogenism (polycystic ovarian syndrome), and other disorders where insulin resistance is a component, said method comprising the administration of an effective amount of a compound of Claim 1.

26. canceled

27. canceled

28. canceled

29. canceled

30. canceled

31. canceled

32. canceled

33. (original) A pharmaceutical composition comprising (1) a compound of Claim 1, (2) one or more compounds selected from the group consisting of

(a) insulin sensitizers including (i) PPAR gamma agonists such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, rosiglitazone, and the like), and compounds disclosed in WO97/27857, 97/28115, 97/28137 and 97/27847; (ii) biguanides such as metformin and phenformin;

(iii) protein tyrosine phosphatase-1B (PTP-1B) inhibitors, and (iv) dipeptidyl peptidase IV (DP-IV) inhibitors;

(b) insulin or insulin mimetics;

(c) sulfonylureas such as tolbutamide and glipizide, or related materials;

(d) α-glucosidase inhibitors (such as acarbose);

(e) cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, itavastatin, ZD-4522 and other statins), (ii) sequestrants (cholestyramine, colestipol, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonists such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and benzafibrate), (v) PPARα/γdual agonists, such as KRP-297, (vi) inhibitors of cholesterol absorption, such as for example beta-sitosterol, (vii) acyl CoA:cholesterol acyltransferase inhibitors, such as for example avasimibe, and (viii) anti-oxidants, such as probucol;

(f) PPARδ agonists such as those disclosed in WO97/28149;

(g) antiobesity compounds such as fenfluramine, dexfenfluramine, phentiramine, sulbitramine, orlistat, neuropeptide Y5 inhibitors, and β_3 adrenergic receptor agonists;

(h) an ileal bile acid transporter inhibitor; and

(i) agents intended for use in inflammatory conditions such as aspirin, non-steroidal anti-inflammatory drugs, glucocorticoids, azulfidine, and cyclo-oxygenase 2 selective inhibitors; and

(3) a pharmaceutically acceptable carrier.